

B 7
and systematic diseases (cf. "Hyojun Hinyoki Kagaku", the fifth edition, published in 1998)

IN THE CLAIMS:

Please cancel claims 1-3 without prejudice or disclaimer.

REMARKS

In the Office Action dated June 25, 2002, the Office considered claims 1-4. Claims 1-3 are canceled by this Amendment, leaving claim 4 pending.

Claim Rejections - 35 U.S.C. § 112

The Office rejects claims 1-4 under 35 U.S.C. § 112, second paragraph, as being indefinite. The Office cites to the Manual of Patent Examining Procedure, section 2173.05(u), to assert that recitation of a trademark in a claim renders the claim indefinite. However, the Office fails to identify what word in the claim(s) is allegedly a trademark. "Tamsulosin" is a nonproprietary generic name; it is not a trademark. The generic meaning of tamsulosin is shown in the attached copy of page 689 from the *USP Dictionary of USAN and International Drug Names* (1997). Absent some identification of a trademark in the pending claims, Applicant requests the withdrawal of the rejection for indefiniteness for recitation of a trademark.

The Office also rejects claim 3 as being indefinite for reciting a use but failing to positively recite any method/process steps. Applicant's cancellation of claim 3 renders moot the rejection.